loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for asciminib hydrochloride

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    asciminib hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Takeda circles Ascentage's Scemblix challenger for up to $1.3B
    Takeda circles Ascentage's Scemblix challenger for up to $1.3B

    15 Jun 2024

    // Zoey Becker FIERCE PHARMA

    https://www.fiercepharma.com/pharma/takeda-signs-potentially-rival-novartis-option-deal-ascentage-pharmas-leukemia-tki

    Zoey Becker FIERCE PHARMA
    15 Jun 2024
    Share Share
    Novartis Highlights Scemblix CML Innovation At ASCO, EHA With Phase III Data
    Novartis Highlights Scemblix CML Innovation At ASCO, EHA With Phase III Data

    15 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/15/2882566/0/en/Novartis-highlights-pioneering-innovation-in-CML-with-data-from-Scemblix-Phase-III-ASC4FIRST-study-in-newly-diagnosed-patients-at-ASCO-and-EHA.html

    GLOBENEWSWIRE
    15 May 2024
    Share Share
    Novartis gears up for key expansions of 3 cancer drugs
    Novartis gears up for key expansions of 3 cancer drugs

    24 Apr 2024

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma/novartis-dials-2024-sales-outlook-preps-key-expansions-3-cancer-drugs

    Angus Liu FIERCE PHARMA
    24 Apr 2024
    Share Share
    Novartis Scemblix shows superior MMR rates vs. TKIs in Phase III trial
    Novartis Scemblix shows superior MMR rates vs. TKIs in Phase III trial

    08 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/08/2805043/0/en/Novartis-Scemblix-shows-superior-major-molecular-response-MMR-rates-vs-standard-of-care-TKIs-in-Phase-III-trial-for-newly-diagnosed-patients-with-chronic-myeloid-leukemia.html

    GLOBENEWSWIRE
    08 Jan 2024
    Share Share
    Novartis showcases significant data updates from Kisqali, iptacopan and Scemblix
    Novartis showcases significant data updates from Kisqali, iptacopan and Scemblix

    20 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/11/20/2782908/0/en/Novartis-showcases-significant-data-updates-from-Kisqali-iptacopan-and-Scemblix-at-SABCS-and-ASH.html

    GLOBENEWSWIRE
    20 Nov 2023
    Share Share
    Scemblix's Scemblix (asciminib) Receives Approval in Europe
    Scemblix's Scemblix (asciminib) Receives Approval in Europe

    02 Mar 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/scemblix-epar-medicine-overview_en.pdf

    EMA
    02 Mar 2023
    Share Share